DINGDANG HEALTH (09886) announced its interim results for the six months ended June 30, 2025, reporting group revenue of RMB 2.327 billion, representing a 2.6% year-on-year increase. The company recorded an owner's loss of RMB 51.671 million during the period, a 38.84% decrease compared to the same period last year, with basic loss per share of RMB 0.04.

According to the announcement, the year-on-year revenue growth was driven by the company's optimized city layout strategy, focusing on and deepening its presence in advantageous regions. The company has been developing Beijing, Shanghai, and Shenzhen as "optimal health service gateways for residents," actively expanding and densifying its smart pharmacy network deployment in these locations, which contributed to solid business growth.

Additionally, the company enhanced its supply chain service capabilities in pharmaceutical and product positioning, resulting in significant improvements in overall operational efficiency. The narrowed losses and improved performance were attributed to a gross margin increase to 35.0%, up 1.9 percentage points year-on-year. Meanwhile, refined operations and continuous cost reduction and efficiency enhancement initiatives delivered notable results, leading to significant improvements in profitability.